Non-functional pancreatic neuroendocrine tumor

Summary

Non-functional pancreatic neuroendocrine tumor (MONDO:0004334) is a cancer and 8 clinical trials. Top therapeutic interventions include cabozantinib, ribociclib, and veliparib. A subtype of pancreatic neuroendocrine tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	non-functional pancreatic neuroendocrine tumor
Mondo ID	MONDO:0004334
MeSH	C536126
Orphanet	506075
DOID	DOID:7698
NCIT	C45837
UMLS	C1334977
MedGen	277416
GARD	0022054
Is cancer (heuristic)	yes

Also known as: inactive pancreatic endocrine tumor · inactive pancreatic endocrine tumour · non functioning pancreatic endocrine tumor · non functioning pancreatic endocrine tumour · non-functional pancreatic neuroendocrine tumor · non-functioning endocrine pancreatic tumors · non-functioning endocrine pancreatic tumours · non-functioning EPTs · non-functioning neuroendocrine tumour of pancreas · non-functioning pancreatic endocrine tumor · non-functioning pancreatic endocrine tumour · non-functioning pancreatic NET · non-functioning pancreatic neuroendocrine tumor · non-functioning pancreatic neuroendocrine tumour · non-functioning PNET · non-functioning well differentiated pancreatic endocrine tumor · non-functioning well differentiated pancreatic endocrine tumour · non-functioning well-differentiated NEN of pancreas · non-functioning well-differentiated neuroendocrine neoplasm of pancreas · non-functioning well-differentiated pancreatic NEN (+11 more)

Disease family

This is a subtype of pancreatic neuroendocrine tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › pancreatic neuroendocrine tumor › non-functional pancreatic neuroendocrine tumor

Related subtypes (10): pancreatic delta cell neuroendocrine tumor, pancreatic gastrin-producing neuroendocrine tumor, pancreatic insulin-producing neuroendocrine tumor, somatostatinoma, GRFoma, PPoma, glucagonoma, VIPoma, pancreatic neuroendocrine tumor G1, functional pancreatic neuroendocrine tumor

Subtypes (1): pancreatic non-functioning delta cell tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE4	1
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02759718	PHASE4	UNKNOWN	Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
NCT03375320	PHASE3	ACTIVE_NOT_RECRUITING	Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
NCT02420691	PHASE2	COMPLETED	Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
NCT02831179	PHASE1	WITHDRAWN	Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
NCT03084770	Not specified	UNKNOWN	Asymptomatic Small Pancreatic Endocrine Neoplasms.
NCT03918759	Not specified	COMPLETED	Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs
NCT05566093	Not specified	UNKNOWN	EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
NCT05907824	Not specified	UNKNOWN	Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3
RIBOCICLIB	4	1
VELIPARIB	3	2